PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Flotufolastat F 18→

Flotufolastat F 18 PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not verified
Molecular formula
C63H99[18F]N12O25Si
Molecular weight
1470.631 g/mol
Drug class
18F-labelled prostate-specific membrane antigen (PSMA) PET radiotracerdiagnostic imaging agent
Mechanism of action
Binds prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. PET imaging detects tracer distribution to localise PSMA-expressing prostate cancer lesions; it is a diagnostic radiopharmaceutical, not a therapeutic PSMA inhibitor.
Indications / reported uses
  • PET imaging of PSMA-positive lesions in men with prostate cancer to localise disease for initial staging or suspected recurrence, in conjunction with other diagnostic evaluations under the US PYLARIFY-like? specific product label; use only for the approved product indication and patient group

Sources: NLM DailyMed — Flotufolastat F 18 (POSLUMA) · US FDA — Flotufolastat PET imaging information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Flotufolastat F 18 PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Flotufolastat F 18 Permitted Daily Exposure (PDE) report (the Flotufolastat F 18 PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Flotufolastat F 18 Occupational Exposure Limit (OEL) report (the Flotufolastat F 18 OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.